MNKD - MannKind Corporation
About MannKind Corporation (https://www.mannkindcorp.com)
MannKind Corporation, a biopharmaceutical company, focuses on the development and commercialization of inhaled therapeutic products for endocrine and orphan lung diseases in the United States. It offers Afrezza, an inhaled insulin used to improve glycemic control in adults with diabetes. It also promotes Thyquidity to adult and pediatric endocrinologists, and other healthcare providers for the treatment of hypothyroidism. The company has a license and collaboration agreement with United Therapeutics Corporation. It also has an agreement with NRx Pharmaceuticals to develop a dry powder formulation of ZYESAMI (aviptadil), a synthetic form of human vasoactive intestinal peptide to help protect cells against inflammatory conditions. MannKind Corporation was incorporated in 1991 and is headquartered in Westlake Village, California.
Key Executives
| NAME | TITLE | DOB | SALARY |
|---|---|---|---|
| Michael E. Castagna | Chief Executive Officer & Director | 1976 | $1,611,005 USD |
| David Thomson | Executive Vice President, General Counsel & Secretary | 1967 | $1,021,768 USD |
| Stuart A. Tross | Chief People & Workplace Officer | 1967 | $812,215 USD |
| Christopher Prentiss | Chief Financial Officer | 1975 | $753,319 USD |
| Dominic Marasco | President of Endocrine Business Unit | 1972 | $717,723 USD |
| Sanjay Singh | Executive Vice President of Technical Operations | 1966 | $364,529 USD |
| Ajay Ahuja | Executive VP & Chief Medical Officer | 1970 | – |